妇科癌症的免疫疗法。
Immunotherapy in gynecological cancers.
作者信息
Lorusso Domenica, Ceni Valentina, Daniele Gennaro, Pietragalla Antonella, Salutari Vanda, Muratore Margherita, Nero Camilla, Ciccarone Francesca, Scambia Giovanni
机构信息
Division of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy.
Department of Life Science and Public Health, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
出版信息
Explor Target Antitumor Ther. 2021;2(1):48-64. doi: 10.37349/etat.2021.00033. Epub 2021 Feb 28.
Immunotherapy has changed the natural history of several malignancies that, a decade ago, had a very poor prognosis, such as lung cancer and melanoma. Consequently, many attempts have been done to expand the indications of immunotherapy agents, predominantly immune checkpoint inhibitors (ICIs), in other cancers, including gynecological malignancies. Alongside promising results in cervical and endometrial neoplasms, there are not clear data on the benefit of ICIs as single agent or in combination with antiangiogenic agents in ovarian cancer (OC) and ongoing trials are focusing on combining ICIs with standard chemotherapy or PARP inhibitors. This chapter summarized the evidences of ICIs in gynecological malignancies and report the ongoing trials in cervical, endometrial and OC.
免疫疗法已经改变了几种恶性肿瘤的自然病程，这些肿瘤在十年前预后非常差，比如肺癌和黑色素瘤。因此，人们进行了许多尝试来扩大免疫疗法药物的适应证，主要是免疫检查点抑制剂（ICI），用于其他癌症，包括妇科恶性肿瘤。除了在宫颈癌和子宫内膜肿瘤中取得了令人鼓舞的结果外，关于ICI作为单一药物或与抗血管生成药物联合用于卵巢癌（OC）的益处，目前尚无明确数据，正在进行的试验聚焦于将ICI与标准化疗或PARP抑制剂联合使用。本章总结了ICI在妇科恶性肿瘤中的证据，并报告了在宫颈癌、子宫内膜癌和卵巢癌中正在进行的试验。
Zotero 插件